Cargando…
Real-World Effectiveness and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Indian Patients: A Multi Centric Retrospective Study
INTRODUCTION: Treatment of moderate to severe atopic dermatitis (AD) is a real challenge for the dermatologists. Dupilumab is the first targeted biologic therapy approved for the treatment of children and adults with moderate-to-severe AD. The efficacy and safety of dupilumab in Indian patients is l...
Autores principales: | Dhar, Sandipan, De, Abhishek, Srinivas, Sahana M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375526/ https://www.ncbi.nlm.nih.gov/pubmed/34446954 http://dx.doi.org/10.4103/ijd.ijd_860_20 |
Ejemplares similares
-
Food Allergy in Atopic Dermatitis
por: Dhar, Sandipan, et al.
Publicado: (2016) -
Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
por: Jang, Dong Hyek, et al.
Publicado: (2020) -
A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
por: Kamata, Masahiro, et al.
Publicado: (2021) -
Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
por: Zhou, Bingjing, et al.
Publicado: (2022) -
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)